The value of 3.0 Tesla diffusion-weighted MRI for pelvic nodal staging in patients with early stage cervical cancer

Department of Gynecology and Obstetrics, University Medical Center Utrecht, The Netherlands.
European journal of cancer (Oxford, England: 1990) (Impact Factor: 4.82). 07/2012; 48(18). DOI: 10.1016/j.ejca.2012.06.022
Source: PubMed

ABSTRACT OBJECTIVE: The purpose of this study is to investigate the diagnostic accuracy of 3.0Tesla (3T) diffusion-weighted magnetic resonance imaging (MRI) in addition to conventional MRI for the detection of lymphadenopathy in patients with early stage cervical cancer compared to histopathological evaluation of the systematically removed pelvic lymph nodes as reference standard. METHODS: 68 fédération internationale de gynécologie obstétrique (FIGO) stage Ia2 to IIb cervical cancer patients were included. Sensitivity and specificity rates for two experienced observers were computed for the detection of lymphatic metastasis. Reproducibility of conventional MRI was tested by kappa statistics. The variables included in the analysis were: size of the long axis, short axis, ratio short to long axis and apparent diffusion coefficient (ADC). RESULTS: Nine patients had 15 positive pelvic nodes at histopathological examination. The sensitivity and specificity of lymphatic metastasis detection by predefined conventional MRI characteristics was 33% (95% Confidence Interval (CI) 3-64) and 83% (95% CI 74-93) on patient level, and 33% (95% CI 7-60) and 97% (95% CI 95-99) on regional level respectively for observer 1. For observer 2 the sensitivity was 33% (95% CI 3-64) and the specificity 93% (95% CI 87-100) on patient level, and 25% (95% CI 1-50) and 98% (95% CI 97-100) on regional level, respectively. The kappa-value for reproducibility of metastasis detection on regional level was 0.50. The short axis diameter showed the highest diagnostic accuracy (area under the curve (AUC)=0.81 95% CI 0.70-0.91); ADC did not improve diagnostic accuracy (AUC=0.83 95% CI 0.73-0.93). CONCLUSIONS: Diffusion-weighted MRI did not result in additional diagnostic value compared to conventional MRI.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Dramatic advances in image quality over the past few years have made diffusion-weighted magnetic resonance imaging (DW-MRI) a promising tool for rectal lesion evaluation. DW-MRI derives its image contrast from differences in the motion of water molecules between tissues. Such imaging can be performed quickly without the need for the administration of exogenous contrast medium. The technique yields qualitative and quantitative information that reflects changes at a cellular level and provides information about tumor cellularity and the integrity of cell membranes. The sensitivity to diffusion is obtained by applying two bipolar diffusion-sensitizing gradients to a standard T2-weighted spin echo sequence. The diffusion-sensitivity can be varied by adjusting the “b-factor”, which represents the gradient duration, gradient amplitude and the time interval between the two gradients. The higher the b-value, the greater the signal attenuation from moving water protons. In this review, technical considerations relatively to image acquisition and to quantification methods applied to rectal DW-MRI are discussed. The current clinical applications of DW-MRI, either in the field of inflammatory or neoplastic rectal disease are reviewed. Also, limitations, mainly in terms of persistent lack of standardization or evaluation of tumoral response, and future directions of rectal DW-MRI are discussed. The potential utility of DW-MRI for the evaluation of rectal tumor response is on its way to being admitted but future well-designed and multicenter studies, as well as standardization of DW-MRI, are still required before a consensus can be reached upon how and when to use DW-MRI.
    Critical Reviews in Oncology/Hematology 12/2014; 92(3). DOI:10.1016/j.critrevonc.2014.07.002 · 4.05 Impact Factor
  • Physics in Medicine and Biology 10/2014; 59(21):R349-R369. DOI:10.1088/0031-9155/59/21/R349 · 2.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Because of the widespread use of cytologic screening programs in industrialized nations, cervical carcinoma is being diagnosed in younger patients and at an earlier stage. The traditional therapy for early-stage disease is radical hysterectomy with pelvic lymphadenectomy, which leads to infertility. In the past 20 years, fertility-sparing therapies, such as cervical conization and radical trachelectomy, have emerged and show good oncologic and obstetric outcomes. The selection criteria for vaginal radical trachelectomy include stages IA2 and IB1, a tumor that is smaller than 2 cm, distance from the internal os of at least 1 cm, limited stromal invasion, and no nodal or extracervical extension. Magnetic resonance (MR) imaging accurately depicts these criteria and is a necessary tool in the preoperative evaluation of patients with cervical carcinoma who are eligible for fertility-sparing surgery. The MR imaging report must provide the following pieces of information for adequate surgical planning: tridimensional diameters of the lesion, uterine and cervical lengths, the degree of stromal invasion, distance from the internal os, and the presence of extracervical or nodal involvement. Because patients also undergo follow-up MR imaging, radiologists must be familiar with the postoperative imaging appearance of the cervix. After trachelectomy, the uterovaginal anastomosis may appear end-to-end or with a neoposterior vaginal fornix. Vaginal wall thickening, hematomas, lymphoceles, and hematometra secondary to isthmic stenosis may be seen. The normal postoperative appearance must be differentiated from recurrent disease, which is seen as a mass with intermediate to high signal intensity in the vaginal vault or parametrium on T2-weighted images. Functional imaging, including diffusion-weighted and dynamic contrast-enhanced imaging, may help characterize recurrence. ©RSNA, 2014.
    Radiographics 07/2014; 34(4):1099-1119. DOI:10.1148/rg.344130009 · 2.73 Impact Factor


Available from
May 21, 2014